HPV+ Recurrent/Metastatic Head and Neck Cancer - Pipeline Insight, 2024

This “HPV+ Recurrent/Metastatic Head and Neck Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

HPV+ Recurrent/Metastatic Head and Neck Cancer: Understanding

HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview

Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas. Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. These symptoms may also be caused by other, less serious conditions. It is important to check with a doctor or dentist about any of these symptoms. Infection with high-risk human papillomaviruses (HPVs) has recently been implicated in the pathogenesis of HNSCCs. It is now widely accepted that high-risk HPV is a cause of almost all cervical cancers as well as some forms of HNSCCs. HPV-related HNSCCs are increasing. HPV-related HNSCCs and HPV-unrelated HNSCCs differ with respect to the molecular mechanisms underlying their oncogenic processes. HPV-related HNSCCs are known to have a better prognosis response to treatment as compared with HPV-unrelated HNSCCs. Therefore, in recent years, it has been required to accurately discriminate between HPV-related and HPV-unrelated HNSCCs. To diagnose the HPV-related HNSCCs, various methods including P16 immunohistochemistry, FISH, and genetic analyses of the HPV gene from histopathological and liquid biopsy specimens have been employed. HPV is a DNA virus that infects the skin and mucous membranes. More than 100 types of HPV have been classified to date. Additionally, at least 12% of oropharyngeal cancer, 3% of oral cancer, and 30-60% of pharyngeal carcinoma cases are caused by HPV infection. In general, HPV-positive oropharyngeal carcinoma is highly susceptible to radiation and anticancer drugs and has a better prognosis compared with HPV-negative cancer. People who are at risk of head and neck cancers-particularly those who use tobacco-should talk with their doctor about ways to stop using tobacco to reduce their risk. Avoiding oral HPV infection can reduce the risk of HPV-associated head and neck cancers. In June 2020, the Food and Drug Administration granted accelerated approval of the HPV vaccine Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in persons aged 9 through 45 years. Head and neck cancer treatment can include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of treatments. The treatment plan for an individual patient depends on a number of factors, including the location of the tumor, the stage of the cancer, and the person’s age and general health.

“HPV+ Recurrent/Metastatic Head and Neck Cancer- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape is provided which includes the disease overview and HPV+ Recurrent/Metastatic Head and Neck Cancer treatment guidelines. The assessment part of the report embraces, in depth HPV+ Recurrent/Metastatic Head and Neck Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HPV+ Recurrent/Metastatic Head and Neck Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HPV+ Recurrent/Metastatic Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HPV+ Recurrent/Metastatic Head and Neck Cancer.

HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs Chapters

This segment of the HPV+ Recurrent/Metastatic Head and Neck Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs

CUE 101: Cue BiopharmaCue Biopharma is advancing a pipeline of targeted interleukin 2 (IL-2)-based immunotherapies for multiple types of cancers with high unmet needs. The CUE-100 series of biologics have the potential to improve efficacy and reduce the severe toxicities associated with non-specific IL-2 cancer immunotherapies. CUE-101, has already demonstrated clinical activity and favorable tolerability as a monotherapy in a Phase 1 trial in patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

BNT 113: Bio NTech BNT113 is an mRNA cancer vaccine encoding two oncoproteins, E6 and E7,that are frequently found in HPV16+ solid cancers aiming to trigger a strong and precise immune response in patients with HPV16+ head and neck squamous cell carcinoma (HNSCC). BNT113 is currently being evaluated in a Phase 2 study, AHEAD-MERIT, in combination with Merck’s pembrolizumab, a PD-1 inhibitor, vs. pembrolizumab alone in patients with unresectable recurrent or metastatic HPV+ PD-1+ HNSCCs. Results from an investigator-initiated Phase 1/2 basket trial, HARE-40, in patients with HPV16+ cancers showed that BNT113 treatment induces potent, antigen-specific Tcellresponses.

HPV+ Recurrent/Metastatic Head and Neck Cancer: Therapeutic Assessment

This segment of the report provides insights about the different HPV+ Recurrent/Metastatic Head and Neck Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in HPV+ Recurrent/Metastatic Head and Neck Cancer

There are approx. 5+ key companies which are developing the therapies for HPV+ Recurrent/Metastatic Head and Neck Cancer. The companies which have their HPV+ Recurrent/Metastatic Head and Neck Cancer drug candidates in the most advanced stage, i.e. phase II include, BioNTech.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HPV+ Recurrent/Metastatic Head and Neck Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HPV+ Recurrent/Metastatic Head and Neck Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HPV+ Recurrent/Metastatic Head and Neck Cancer drugs.

HPV+ Recurrent/Metastatic Head and Neck Cancer Report Insights

• HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

HPV+ Recurrent/Metastatic Head and Neck Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing HPV+ Recurrent/Metastatic Head and Neck Cancer drugs?
• How many HPV+ Recurrent/Metastatic Head and Neck Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HPV+ Recurrent/Metastatic Head and Neck Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HPV+ Recurrent/Metastatic Head and Neck Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HPV+ Recurrent/Metastatic Head and Neck Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioNTech
• Cue Biopharma
• Hookipa Pharma

Key Products

• CUE 101
• BNT 113
• HB 201

This product will be delivered within 2 business days.